4487-50-7Relevant academic research and scientific papers
Structural and vibrational investigation of 2-amino-4-nitropyridine crystal
Oszust,Talik,Pietraszko,Marchewka,Baran
, p. 53 - 63 (1997)
The X-ray structure of 2-amino-4-nitropyridine was determined at room temperature. The crystal belongs to the P2(I)/c space group of the monoclinic system (Z = 4, a = 6.7290(10), b = 10.946(2), c = 9.060(2) A, β = 100.03(3) deg) and is built of layers parallel to the (102) crystallographic plane. The molecules in the layer are joined into centrosymmetric dimers by two N-H···N hydrogen bonds (N···N distance = 3.011(3) A), which form rings of C(i) symmetry. The other N-H bonds of the amino groups are involved in N-H···O hydrogen bonds with the oxygen atoms of the nitro groups (N···O distance = 3.054(3) A). These hydrogen bonds join the dimers into an infinite plane. The powder IR and Raman spectra (4000-80 cm-1) were measured for normal and deuterated crystals and are discussed with respect to the crystal structure. The N-H stretching vibrations behave as the stretching vibrations of two almost independent hydrogen bonds. Strong A(g)-A(u)-type splitting is observed for the stretching vibrations of the N-H···N type hydrogen bonds.
Crystal Forms And Salt Forms Of 7h-Pyrrolo[2,3-D]Pyrimidine Compounds And Preparation Method Thereof
-
, (2019/08/01)
The present invention discloses crystal forms and salt forms of a 7H-pyrrolo[2,3-d]pyrimidine compounds and preparation methods thereof, and further discloses use of the crystal forms and the salt forms in the manufacture of a medicament for treating arthritis.
JANUS KINASE INHIBITOR
-
Paragraph 0059; 0062, (2018/04/19)
Disclosed are a series of Janus kinase inhibitors, and particularly discolsed are a compound or pharmaceutically acceptable salts thereof of Formula (I) and use thereof in the preparation of drugs for treating Janus kinase (JAK)-related diseases.
SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF
-
Page/Page column 51, (2012/02/01)
This invention provides compounds of formula (I): wherein R1a, R1b, R1c, R2a, R2b, R2c, and R2d have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.
SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF
-
Page/Page column 72-73, (2011/12/04)
This invention provides compounds of formula (I): wherein R1a, R1, R2a, and R2b have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.
Design and optimization of potent and orally bioavailable tetrahydronaphthalene raf inhibitors
Gould, Alexandra E.,Adams, Ruth,Adhikari, Sharmila,Aertgeerts, Kathleen,Afroze, Roushan,Blackburn, Christopher,Calderwood, Emily F.,Chau, Ryan,Chouitar, Jouhara,Duffey, Matthew O.,England, Dylan B.,Farrer, Cheryl,Forsyth, Nancy,Garcia, Khristofer,Gaulin, Jeffery,Greenspan, Paul D.,Guo, Ribo,Harrison, Sean J.,Huang, Shih-Chung,Iartchouk, Natalia,Janowik, Dave,Kim, Mi-Sook,Kulkarni, Bheemashankar,Langston, Steven P.,Liu, Jane X.,Ma, Li-Ting,Menon, Saurabh,Mizutani, Hirotake,Paske, Erin,Renou, Christelle C.,Rezaei, Mansoureh,Rowland, R. Scott,Sintchak, Michael D.,Smith, Michael D.,Stroud, Stephen G.,Tregay, Ming,Tian, Yuan,Veiby, Ole P.,Vos, Tricia J.,Vyskocil, Stepan,Williams, Juliet,Xu, Tianlin,Yang, Johnny J.,Yano, Jason,Zeng, Hongbo,Zhang, Dong Mei,Zhang, Qin,Galvin, Katherine M.
experimental part, p. 1836 - 1846 (2011/05/30)
Inhibition of mutant B-Raf signaling, through either direct inhibition of the enzyme or inhibition of MEK, the direct substrate of Raf, has been demonstrated preclinically to inhibit tumor growth. Very recently, treatment of B-Raf mutant melanoma patients with a selective B-Raf inhibitor has resulted in promising preliminary evidence of antitumor activity. This article describes the design and optimization of tetrahydronaphthalene-derived compounds as potent inhibitors of the Raf pathway in vitro and in vivo. These compounds possess good pharmacokinetic properties in rodents and inhibit B-Raf mutant tumor growth in mouse xenograft models.
